The company's total revenue surged 96% year over year to reach $2.31 billion, propelled by U.S. commercial sales outperforming government revenue for the first time. However, corporate clients are increasingly opting for shorter-term trials that can be canceled more easily, complicating the long-term sales pipeline. Chief Executive Alex Karp confirmed that client interactions are speeding up even as individual contract lengths contract. Despite these headwinds, leadership raised its full-year outlook for domestic commercial growth to exceed 143%.
Key points
Demand for artificial intelligence deployments is driving massive commercial expansion, y…: Demand for artificial intelligence deployments is driving massive commercial expansion, yet client commitments are shifting toward shorter durations.
A steep sequential drop in enterprise contract values threatens future revenue predictabi…: A steep sequential drop in enterprise contract values threatens future revenue predictability despite raised full-year targets.
Corporate customers can cancel shorter trial agreements more easily, creating underlying…: Corporate customers can cancel shorter trial agreements more easily, creating underlying vulnerability for future quarters.
Sources checked by our analysis pipeline: 1
Palantir delivered such a huge third-quarter earnings report on Monday that its press release even bragged that the numbers were “crushing consensus expectations.”
Yet, retail investors were lukewarm on the company on Tuesday, with the stock trading slightly down. That’s because Palantir’s enterprise sales, its big growth area, showed signs of slowing.
First, the good news for the company’s investors. Revenue grew 96% year over year to $2.31 billion, the first time it has ever surpassed the $2 billion mark. Palantir’s revenue, which also grew 20% from the previous quarter, beat analysts’ expectations of $2.18 billion. Palantir also reported adjusted earnings per share of $0.44 versus analysts’ expectations of $0.41. The company even upped its revenue guidance for the full year. Normally, that alone would send a stock soaring.
The clincher was that Palantir’s U.S. commercial revenue surpassed U.S. government revenue for the first time ever. The company reported $984 million in commercial contracts (up 148% from the year-ago quarter), versus $953 million in U.S. government revenue.
The reason for all this love from enterprises? They are signing up for…
Strong operational execution sparked an immediate market rally as the company delivered outsized financial results. Investors responded positively to the twin catalyst of outperforming past expectations and setting an ambitious forward outlook. This performance highlights sustained momentum, satisfying market demand that exceeded previous consensus forecasts.
Executive leadership attributed the latest positive financial performance to an expanding base of high-quality enterprise clients. Chief Financial Officer Mark Long confirmed that this growing roster of customers is directly accelerating corporate revenue. The results underline a sharp market appetite for specialized computing hardware tailored specifically to complex enterprise workloads.
Commercial momentum across core therapeutic areas provided a substantial revenue lift during the third-quarter period. Robust patient demand for targeted treatments within the company's major product portfolios underpinned the advance. These results demonstrate sustained market adoption for the drugmaker's leading specialty therapies.